TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $319,149 | -97.2% | 35,699 | -95.1% | 0.00% | -97.6% |
| Q2 2023 | $11,272,120 | +1115.6% | 733,862 | +1679.9% | 0.04% | +192.9% |
| Q1 2023 | $927,285 | -91.3% | 41,231 | -91.9% | 0.01% | -92.8% |
| Q4 2022 | $10,663,955 | +27.9% | 507,083 | +49.8% | 0.19% | +22.0% |
| Q3 2022 | $8,339,000 | +65.6% | 338,424 | +62.8% | 0.16% | +14.4% |
| Q2 2022 | $5,037,000 | +17.4% | 207,895 | +24.8% | 0.14% | +20.9% |
| Q1 2022 | $4,291,000 | +220.7% | 166,520 | +286.4% | 0.12% | +173.8% |
| Q4 2021 | $1,338,000 | +303.0% | 43,095 | +89.2% | 0.04% | +281.8% |
| Q2 2021 | $332,000 | +50.2% | 22,778 | +157.5% | 0.01% | -15.4% |
| Q1 2021 | $221,000 | – | 8,847 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |